Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients

Basit Öğe Kaydı
dc.contributor.authorAkar, Servet
dc.contributor.authorCetin, Pinar
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorKaradag, Omer
dc.contributor.authorSari, Ismail
dc.contributor.authorCinar, Muhammed
dc.contributor.authorYilmaz, Sedat
dc.contributor.authorOnat, Ahmet Mesut
dc.contributor.authorKisacik, Bunyamin
dc.contributor.authorErden, Abdulsamet
dc.contributor.authorBalkarli, Ayse
dc.contributor.authorKucuksahin, Orhan
dc.contributor.authorOner, Sibel Yilmaz
dc.contributor.authorSenel, Soner
dc.contributor.authorTufan, Abdurrahman
dc.contributor.authorDireskeneli, Haner
dc.contributor.authorOksuz, Ferhat
dc.contributor.authorPehlivan, Yavuz
dc.contributor.authorBayindir, Ozun
dc.contributor.authorKeser, Gokhan
dc.contributor.authorAksu, Kenan
dc.contributor.authorOmma, Ahmet
dc.contributor.authorKasifoglu, Timucin
dc.contributor.authorUnal, Ali Ugur
dc.contributor.authorYildiz, Fatih
dc.contributor.authorBalci, Mehmet Ali
dc.contributor.authorYavuz, Sule
dc.contributor.authorErten, Sukran
dc.contributor.authorOzgen, Metin
dc.contributor.authorSayarlioglu, Mehmet
dc.contributor.authorDogru, Atalay
dc.contributor.authorYildirim, Gozde
dc.contributor.authorOner, Fatma Alibaz
dc.contributor.authorTezcan, Mehmet Engin
dc.contributor.authorPamuk, Omer Nuri
dc.contributor.authorOnen, Fatos
dc.date.accessioned2019-10-27T10:04:39Z
dc.date.available2019-10-27T10:04:39Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectiveApproximately 30-45% of patients with familial Mediterranean fever (FMF) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine-unresponsive or colchicine-intolerant FMF patients are limited; the most promising alternatives seem to be anti-interleukin-1 (anti-IL-1) agents. Here we report our experience with the off-label use of anti-IL-1 agents in a large group of FMF patients. MethodsIn all, 21 centers from different geographical regions of Turkey were included in the current study. The medical records of all FMF patients who had used anti-IL-1 treatment for at least 6 months were reviewed. ResultsIn total, 172 FMF patients (83 [48%] female, mean age 36.2 years [range 18-68]) were included in the analysis; mean age at symptom onset was 12.6 years (range 1-48), and the mean colchicine dose was 1.7 mg/day (range 0.5-4.0). Of these patients, 151 were treated with anakinra and 21 with canakinumab. Anti-IL-1 treatment was used because of colchicine-resistant disease in 84% and amyloidosis in 12% of subjects. During the mean 19.6 months of treatment (range 6-98), the yearly attack frequency was significantly reduced (from 16.8 to 2.4; P < 0.001), and 42.1% of colchicine-resistant FMF patients were attack free. Serum levels of C-reactive protein, erythrocyte sedimentation rate, and 24-hour urinary protein excretion (5,458.7 mg/24 hours before and 3,557.3 mg/24 hours after) were significantly reduced. ConclusionAnti-IL-1 treatment is an effective alternative for controlling attacks and decreasing proteinuria in colchicine-resistant FMF patients.en_US
dc.identifier.doi10.1002/acr.23446en_US
dc.identifier.endpage1094en_US
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.issue7en_US
dc.identifier.pmid28992387en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1090en_US
dc.identifier.urihttps://doi.org/10.1002/acr.23446
dc.identifier.urihttps://hdl.handle.net/11454/30263
dc.identifier.volume70en_US
dc.identifier.wosWOS:000436403100017en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofArthritis Care & Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleNationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu